◎ Sugi Atlas

Atlas / Drug / Terbutaline

Terbutaline

drug
On this page

Also known as AsthmasianTerbutalinTerbutalinaSID90341646TERBUTALINE HEMISULFATE

Summary

Terbutaline (CHEMBL1760) is an approved small-molecule β-adrenergic agonist (ATC R03CC53) targeting ADRB1 and ADRB2; indicated across 6 conditions including obstructive lung disease and chronic obstructive pulmonary disease.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: R03CC53 (+2 more)
  • Targets: 2 (ADRB1, ADRB2)
  • Indications: 6 conditions
  • Clinical trials: 29
  • Chemistry: 225.28 Da · C12H19NO3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1760
NameTerbutaline
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5403
ChEBICHEBI:9449
ATCR03CC53, R03AC03, R03CC03
Molecular formulaC12H19NO3
Molecular weight225.28
InChIKeyXWTYSIMOBUGWOL-UHFFFAOYSA-N

SMILES: CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O

IUPAC name: 5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol

ChEBI definition: A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.

Pharmacological roles (ChEBI): β-adrenergic agonist, EC 3.1.1.7 (acetylcholinesterase) inhibitor, anti-asthmatic drug, bronchodilator agent, sympathomimetic agent, tocolytic agent, hypoglycemic agent.

Also known as: Asthmasian, Terbutalin, Terbutalina, Terbutaline, terbutaline, SID90341646, TERBUTALINE, TERBUTALINE HEMISULFATE

Parent form; salt/anhydrous children: CHEMBL1160544, CHEMBL1315867

Patent coverage: 9,306 distinct patent families (37,588 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ADRB1β1-adrenoceptorPartial agonist3.90%P08588
ADRB2β2-adrenoceptorPartial agonist7.30.4%P07550

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Beta-2 adrenergic receptor, Beta-2 adrenergic receptor.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ADRB25.6Kd2512nMCHEMBL_ACT_13449577
ADRB25.6Kd2510nMCHEMBL_ACT_2688154
ADRB25.5EC503162nMCHEMBL_ACT_6284212
Q280445.4Kd3980nMCHEMBL_ACT_491778
Q280445.35Kd4480nMCHEMBL_ACT_897071

Target pathways

Aggregated over 2 target gene(s): ADRB1, ADRB2.

Top Reactome pathways

16 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction2ADRB1, ADRB2
Signaling by GPCR2ADRB1, ADRB2
Class A/1 (Rhodopsin-like receptors)2ADRB1, ADRB2
Amine ligand-binding receptors2ADRB1, ADRB2
GPCR downstream signalling2ADRB1, ADRB2
Adrenoceptors2ADRB1, ADRB2
G alpha (s) signalling events2ADRB1, ADRB2
GPCR ligand binding2ADRB1, ADRB2
Membrane Trafficking1ADRB2
Metabolism of proteins1ADRB2
Vesicle-mediated transport1ADRB2
Deubiquitination1ADRB2
Ub-specific processing proteases1ADRB2
Post-translational protein modification1ADRB2
Cargo recognition for clathrin-mediated endocytosis1ADRB2
Clathrin-mediated endocytosis1ADRB2

Dominant GO biological processes

GO termTargets
diet induced thermogenesis2
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure2
adenylate cyclase-activating G protein-coupled receptor signaling pathway2
response to cold2
positive regulation of cardiac muscle cell apoptotic process2
heat generation2
negative regulation of multicellular organism growth2
positive regulation of MAPK cascade2
brown fat cell differentiation2
adenylate cyclase-activating adrenergic receptor signaling pathway2
positive regulation of cold-induced thermogenesis2
signal transduction2
G protein-coupled receptor signaling pathway2
positive regulation of heart rate by epinephrine-norepinephrine1
positive regulation of the force of heart contraction by epinephrine-norepinephrine1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
obstructive lung disease4MONDO:0002267HP:0006536

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341
asthma3MONDO:0004979MONDO:0004979
neuralgia2MONDO:0021667EFO:0005762
autoimmune thrombocytopenic purpura2MONDO:0008558EFO:0007160
type 1 diabetes mellitus1MONDO:0005147MONDO:0005147

Clinical trials

Total trials: 29.

Phase distribution

PhaseTrials
PHASE39
Not specified9
PHASE45
PHASE23
PHASE2/PHASE32
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00124995PHASE4COMPLETEDTrial of Terbutaline for the Treatment of Status Asthmaticus in Children
NCT00802230PHASE4COMPLETEDPharmacodynamic Study of Carvedilol Versus Metoprolol in Heart Failure
NCT00914797PHASE4UNKNOWNTerbutaline Concentrations in Blood and Urine
NCT01651962PHASE4UNKNOWNIntravenous Terbutaline to Facilitate Labor Epidural Catheter Placement
NCT03106753PHASE4TERMINATEDSuccess of External Cephalic Version Study
NCT06980727PHASE3NOT_YET_RECRUITINGComparative Efficacy of IV Dexamethasone vs. Nebulized Terbutaline for Renal Colic Pain in the ED
NCT00244608PHASE3COMPLETEDA Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®
NCT00259766PHASE3COMPLETEDSHARE - Symbicort and Health Economics in a Real Life Evaluation
NCT00421122PHASE3COMPLETEDEfficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
NCT00837967PHASE3COMPLETEDStudy to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients
NCT00839800PHASE3COMPLETEDStudy to Investigate the Efficacy of Symbicort® SMART.
NCT00849095PHASE3COMPLETEDPrn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma
NCT01096017PHASE3COMPLETEDTo Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study
NCT02115256PHASE2/PHASE3TERMINATEDStudy to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline
NCT04973345PHASE2/PHASE3WITHDRAWNTerbutaline Sulfate in Adults With Asthma
NCT06626620PHASE3COMPLETEDRandomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma
NCT00989833PHASE2COMPLETEDComparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients
NCT04481282PHASE2UNKNOWNThe Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia
NCT05494307PHASE2UNKNOWNThe Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia
NCT00607503PHASE1COMPLETEDA Pilot Study to Evaluate the Safety of Terbutaline in Children With Type 1 Diabetes
NCT05193968Not specifiedRECRUITINGHot Flashes and Neurovascular Function in Women
NCT00185887Not specifiedCOMPLETEDNitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation
NCT00518141Not specifiedCOMPLETEDUse of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)
NCT00974051Not specifiedCOMPLETEDUse of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia
NCT02557581Not specifiedUNKNOWNcAMP Signaling and Muscle Adaptations
NCT02712658Not specifiedCOMPLETEDRole of K+ and Ca2+ in Development of Muscle Fatigue
NCT03565302Not specifiedUNKNOWNBeta2-adrenergic Agonism and Muscle Remodelling
NCT04468568Not specifiedCOMPLETEDIn Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
NCT05326269Not specifiedCOMPLETEDAcute Tocolysis With Terbutaline for Suspected Fetal Distress

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

238 molecules share ≥1 primary target. Top 100 by shared-target count:

MoleculeSourceStatusShared targets
DesloratadineChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2
DihydroergotamineChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2
OLODATEROLChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2
PramipexoleChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2
TAMSULOSINChEMBL + PubChemPhase 4 (approved)ADRB1, ADRB2
ACEBUTOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
ALBUTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2
AMITRIPTYLINEChEMBLPhase 4 (approved)ADRB1, ADRB2
ARFORMOTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2
ARIPIPRAZOLEChEMBLPhase 4 (approved)ADRB1, ADRB2
ATENOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
BENPERIDOLChEMBLPhase 4 (approved)ADRB1, ADRB2
BETAXOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
BISOPROLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
BREXPIPRAZOLEChEMBLPhase 4 (approved)ADRB1, ADRB2
BROMOCRIPTINEChEMBLPhase 4 (approved)ADRB1, ADRB2
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)ADRB1, ADRB2
CARTEOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
CARVEDILOLChEMBLPhase 4 (approved)ADRB1, ADRB2
CELIPROLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
CHLORHEXIDINEChEMBLPhase 4 (approved)ADRB1, ADRB2
CLEMASTINEChEMBLPhase 4 (approved)ADRB1, ADRB2
CLOMIPRAMINEChEMBLPhase 4 (approved)ADRB1, ADRB2
CLOTRIMAZOLEChEMBLPhase 4 (approved)ADRB1, ADRB2
DARIFENACINChEMBLPhase 4 (approved)ADRB1, ADRB2
DOBUTAMINEChEMBLPhase 4 (approved)ADRB1, ADRB2
DOMPERIDONEChEMBLPhase 4 (approved)ADRB1, ADRB2
EPINEPHRINEChEMBLPhase 4 (approved)ADRB1, ADRB2
ERGOTAMINEChEMBLPhase 4 (approved)ADRB1, ADRB2
ESMOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
FENOTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2
FLUSPIRILENEChEMBLPhase 4 (approved)ADRB1, ADRB2
FORMOTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2
INDACATEROLChEMBLPhase 4 (approved)ADRB1, ADRB2
ISOPROTERENOLChEMBLPhase 4 (approved)ADRB1, ADRB2
LABETALOLChEMBLPhase 4 (approved)ADRB1, ADRB2
LEVOBUNOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
METOPROLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
MONTELUKASTChEMBLPhase 4 (approved)ADRB1, ADRB2
NADOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
NEBIVOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
NITAZOXANIDEChEMBLPhase 4 (approved)ADRB1, ADRB2
NOREPINEPHRINEChEMBLPhase 4 (approved)ADRB1, ADRB2
NORTRIPTYLINEChEMBLPhase 4 (approved)ADRB1, ADRB2
OXPRENOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
PHENYLEPHRINEChEMBLPhase 4 (approved)ADRB1, ADRB2
PIMOZIDEChEMBLPhase 4 (approved)ADRB1, ADRB2
PINDOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
PRACTOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
PRENYLAMINEChEMBLPhase 4 (approved)ADRB1, ADRB2
PRIMAQUINEChEMBLPhase 4 (approved)ADRB1, ADRB2
PROPAFENONEChEMBLPhase 4 (approved)ADRB1, ADRB2
PROPRANOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
RANOLAZINEChEMBLPhase 4 (approved)ADRB1, ADRB2
RIFAMPINChEMBLPhase 4 (approved)ADRB1, ADRB2
RIFAXIMINChEMBLPhase 4 (approved)ADRB1, ADRB2
RITODRINEChEMBLPhase 4 (approved)ADRB1, ADRB2
SALMETEROLChEMBLPhase 4 (approved)ADRB1, ADRB2
SOTALOLChEMBLPhase 4 (approved)ADRB1, ADRB2
SUNITINIBChEMBLPhase 4 (approved)ADRB1, ADRB2
TAMOXIFENChEMBLPhase 4 (approved)ADRB1, ADRB2
TEGASERODChEMBLPhase 4 (approved)ADRB1, ADRB2
THIORIDAZINEChEMBLPhase 4 (approved)ADRB1, ADRB2
TIMOLOLChEMBLPhase 4 (approved)ADRB1, ADRB2
TIOCONAZOLEChEMBLPhase 4 (approved)ADRB1, ADRB2
VALDECOXIBChEMBLPhase 4 (approved)ADRB1, ADRB2
VILANTEROLChEMBLPhase 4 (approved)ADRB1, ADRB2
AROTINOLOLChEMBLPhase 3ADRB1, ADRB2
LISURIDEChEMBLPhase 3ADRB1, ADRB2
OTILONIUM BROMIDEChEMBLPhase 3ADRB1, ADRB2
PROCATEROLChEMBLPhase 3ADRB1, ADRB2
URAPIDILChEMBLPhase 3ADRB1, ADRB2
ABEDITEROLChEMBLPhase 2ADRB1, ADRB2
ALPRENOLOLChEMBLPhase 2ADRB1, ADRB2
AMOSULALOLChEMBLPhase 2ADRB1, ADRB2
BENZETHONIUMChEMBLPhase 2ADRB1, ADRB2
BEVANTOLOLChEMBLPhase 2ADRB1, ADRB2
BOPINDOLOLChEMBLPhase 2ADRB1, ADRB2
CIMATEROLChEMBLPhase 2ADRB1, ADRB2
CLENBUTEROLChEMBLPhase 2ADRB1, ADRB2
CLORPRENALINEChEMBLPhase 2ADRB1, ADRB2
DENOPAMINEChEMBLPhase 2ADRB1, ADRB2
DEXPROPRANOLOLChEMBLPhase 2ADRB1, ADRB2
DIHYDREXIDINEChEMBLPhase 2ADRB1, ADRB2
DOMIPHENChEMBLPhase 2ADRB1, ADRB2
FLESTOLOLChEMBLPhase 2ADRB1, ADRB2
LEVISOPRENALINEChEMBLPhase 2ADRB1, ADRB2
LEVOPROPRANOLOLChEMBLPhase 2ADRB1, ADRB2
LYSERGIDEChEMBLPhase 2ADRB1, ADRB2
MILVETEROLChEMBLPhase 2ADRB1, ADRB2
NEMONAPRIDEChEMBLPhase 2ADRB1, ADRB2
NYLIDRINChEMBLPhase 2ADRB1, ADRB2
RAFABEGRONChEMBLPhase 2ADRB1, ADRB2
SIBENADETChEMBLPhase 2ADRB1, ADRB2
SOFALCONEChEMBLPhase 2ADRB1, ADRB2
SOLABEGRONChEMBLPhase 2ADRB1, ADRB2
SPIRAMIDEChEMBLPhase 2ADRB1, ADRB2
TALINOLOLChEMBLPhase 2ADRB1, ADRB2
TRETOQUINOLChEMBLPhase 2ADRB1, ADRB2
TULOBUTEROLChEMBLPhase 2ADRB1, ADRB2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot